[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538549":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":43,"centralContacts":47,"locations":53,"responsibleParty":70,"collaborators":42,"id":73,"slug":42,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":42,"enrollmentInfo":82,"targetDuration":42,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":42,"overallStatus":55,"whyStopped":42,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemotherapy and surgery arm","EXPERIMENTAL","Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.",[13,14,15,16],"Procedure: Carboplatin or cisplatin","Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar","Drug: Bevacizumab or biosimilar","Procedure: Cytoreductive surgery",[18,25,32,38],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Carboplatin or cisplatin","Carboplatin of cisplatin for 3-6 cycles",[9],[24],"Paraplatin or Platinol",{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar","Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles",[9],[31],"Taxol, Gemzar, Caelyx",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Bevacizumab or biosimilar","Optional",[9],[37],"Avastin or mvasi",{"type":19,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Cytoreductive surgery","Cytoreductive surgery after chemotherapy",[9],null,[44],{"name":45,"affiliation":5,"role":46},"Ka Yu Tse","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":42,"email":52},"Lesley Lau","CONTACT","852-22554265","lsk382@hku.hk",[54],{"facility":5,"status":55,"city":56,"state":42,"zip":42,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Hong Kong",{"type":58,"coordinates":59},"Point",[60,61],114.17469,22.27832,{"lat":61,"lon":60},[64,66,68],{"name":49,"role":50,"phone":65,"phoneExt":42,"email":42},"852-22554518",{"name":45,"role":50,"phone":51,"phoneExt":42,"email":67},"tseky@hku.hk",{"name":69,"role":46,"phone":42,"phoneExt":42,"email":42},"Ka Yu Tse, MBBS, PhD",{"type":46,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Dr. Ka-Yu Tse","Clinical Associate Professor","100538549",false,"NCT06292286","Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study","SCENIC","Inclusion Criteria:\n\n* Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma\n* \\>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and \u002F or PARPi, at primary setting\n* Platinum-free interval should be \\>=6 months from the last dose of platinum-based chemotherapy\n* Upfront SCR not feasible\n* Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.\n* Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.\n\nExclusion Criteria:\n\n* Non-epithelial or borderline tumors are excluded\n* Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.\n* Patients using more than one line of chemotherapy are excluded.\n* Patients who have platinum-resistant or refractory recurrence are excluded.\n* Patients having second relapse or beyond are excluded.\n* Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment","FEMALE","18 Years",{"count":83,"type":84},18,"ESTIMATED","INTERVENTIONAL",[87],"NA","About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.",[90],"Recurrent Ovarian Carcinoma","2025-06-06",{"date":93,"type":94},"2025-06-11","ACTUAL",{"date":96,"type":94},"2023-11-01",{"date":98,"type":84},"2026-12-31",{"name":5,"class":6},1]